Clinical Trials Logo

Melanoma (Skin) clinical trials

View clinical trials related to Melanoma (Skin).

Filter by:

NCT ID: NCT00006022 Completed - Kidney Cancer Clinical Trials

Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer

Start date: September 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining bryostatin 1 with interleukin-2 may kill more tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of interleukin-2 plus bryostatin 1 in treating patients who have melanoma or kidney cancer that cannot be removed during surgery.

NCT ID: NCT00005971 Completed - Melanoma (Skin) Clinical Trials

Flavopiridol in Treating Patients With Metastatic Malignant Melanoma

Start date: July 4, 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have metastatic malignant melanoma.

NCT ID: NCT00005968 Completed - Melanoma (Skin) Clinical Trials

Irofulven in Treating Patients With Stage IV Melanoma

Start date: November 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients who have stage IV melanoma.

NCT ID: NCT00005961 Completed - Melanoma (Skin) Clinical Trials

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

Start date: June 2000
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of O6-benzylguanine and carmustine in treating patients who have unresectable locally recurrent or metastatic melanoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than once chemotherapy drug may kill more tumor cells.

NCT ID: NCT00005943 Completed - Melanoma (Skin) Clinical Trials

Gene Therapy in Treating Patients With Metastatic Melanoma

Start date: February 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Inserting the gene for interleukin-2 into a person's melanoma cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have metastatic melanoma.

NCT ID: NCT00005875 Completed - Melanoma (Skin) Clinical Trials

Nitrocamptothecin in Treating Patients With Metastatic Melanoma

Start date: January 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have metastatic melanoma.

NCT ID: NCT00005841 Terminated - Melanoma (Skin) Clinical Trials

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Start date: June 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to kill tumor cells. Vaccine therapy plus filgrastim combined with a specific protein may be a more effective treatment for melanoma. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma that has been completely removed during surgery.

NCT ID: NCT00005815 Completed - Melanoma (Skin) Clinical Trials

Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma

Start date: December 1999
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of melanoma by stopping blood flow to the tumor. Combining chemotherapy with thalidomide may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness temozolomide plus thalidomide in treating patients who have stage III or stage IV melanoma that cannot be removed during surgery.

NCT ID: NCT00005633 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Start date: June 1999
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma.

NCT ID: NCT00005615 Completed - Melanoma (Skin) Clinical Trials

Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-Alfa

Start date: July 1997
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining interferon alfa plus radiation therapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of interferon alfa plus radiation therapy in treating patients who have stage III or recurrent melanoma that has been removed by surgery.